PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-108.36%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-9873.13%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-16129.65%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-12933.18%
Negative EPS growth while GNPX is at 34.62%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-12933.18%
Negative diluted EPS growth while GNPX is at 34.62%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
24.22%
Share reduction more than 1.5x GNPX's 80.76%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
24.22%
Diluted share reduction more than 1.5x GNPX's 80.76%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-18.12%
Negative OCF growth while GNPX is at 7.14%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
0.96%
FCF growth under 50% of GNPX's 7.14%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.71%
Negative 10Y OCF/share CAGR while GNPX stands at 91.62%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-63.71%
Negative 5Y OCF/share CAGR while GNPX is at 96.48%. Joel Greenblatt would question the firm’s operational model or cost structure.
-2899.60%
Negative 3Y OCF/share CAGR while GNPX stands at 96.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-30244.22%
Negative 10Y net income/share CAGR while GNPX is at 99.56%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-30244.22%
Negative 5Y net income/share CAGR while GNPX is 96.58%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-27789.91%
Negative 3Y CAGR while GNPX is 96.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-195.85%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-195.85%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
20.77%
Positive short-term equity growth while GNPX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.33%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
14.08%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
11.04%
Debt growth of 11.04% while GNPX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
35.15%
We increase R&D while GNPX cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
3110.63%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.